<DOC>
	<DOC>NCT01208090</DOC>
	<brief_summary>This study will assess the efficacy, safety and tolerability of two doses of ACT 128800 in patients with moderate-to-severe chronic plaque psoriasis.</brief_summary>
	<brief_title>ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Adult males and females aged 18 to 60 years (inclusive) with moderate to severe chronic plaque psoriasis who require systemic treatment. Patients with other forms of psoriasis and patients who are currently treated for autoimmune disorders other than psoriasis. Systemic or topical treatments for psoriasis other than emollients. Ongoing bacterial, viral or fungal infections. History or presence of malignancy. Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>chronic plaque psoriasis</keyword>
	<keyword>Moderate to severe chronic plaque psoriasis</keyword>
</DOC>